These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12873656)

  • 1. Prospective study of fibrinolytic markers and venous thromboembolism.
    Folsom AR; Cushman M; Heckbert SR; Rosamond WD; Aleksic N
    J Clin Epidemiol; 2003 Jun; 56(6):598-603. PubMed ID: 12873656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation.
    Keragala CB; McFadyen JD; Ho H; McCutcheon FM; Liu Z; Stevens H; Monagle P; Chunilal S; Medcalf RL; Tran H
    J Thromb Haemost; 2024 Mar; 22(3):785-793. PubMed ID: 37944898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
    Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA
    Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofibrinolysis in atrial fibrillation.
    Roldán V; Marín F; Marco P; Martínez JG; Calatayud R; Sogorb F
    Am Heart J; 1998 Dec; 136(6):956-60. PubMed ID: 9842006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo.
    Jones CI; Payne DA; Hayes PD; Naylor AR; Bell PR; Thompson MM; Goodall AH
    J Vasc Surg; 2008 Sep; 48(3):715-22. PubMed ID: 18572351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism.
    Bozic M; Stegnar M; Fermo I; Ritonja A; Peternel P; Stare J; D'Angelo A
    Thromb Res; 2000 Nov; 100(4):271-8. PubMed ID: 11113270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.
    Wada K; Takahashi H; Tatewaki W; Takizawa S; Shibata A
    Thromb Res; 1989 Dec; 56(6):661-5. PubMed ID: 2534445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
    Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.
    Vuckovic BA; Djeric MJ; Tomic BV; Djordjevic VJ; Bajkin BV; Mitic GP
    Blood Coagul Fibrinolysis; 2018 Jan; 29(1):19-24. PubMed ID: 28777103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis.
    Barcellona D; Fenu L; Cauli C; Pisu G; Marongiu F
    Thromb Haemost; 2003 Dec; 90(6):1061-4. PubMed ID: 14652637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
    Crowther MA; Roberts J; Roberts R; Johnston M; Stevens P; Skingley P; Patrassi GM; Sartori MT; Hirsh J; Prandoni P; Weitz JI; Gent M; Ginsberg JS
    Thromb Haemost; 2001 Mar; 85(3):390-4. PubMed ID: 11307802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).
    Ohira T; Cushman M; Tsai MY; Zhang Y; Heckbert SR; Zakai NA; Rosamond WD; Folsom AR
    J Thromb Haemost; 2007 Jul; 5(7):1455-61. PubMed ID: 17425663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.
    Comerota AJ; Chouhan V; Harada RN; Sun L; Hosking J; Veermansunemi R; Comerota AJ; Schlappy D; Rao AK
    Ann Surg; 1997 Sep; 226(3):306-13; discussion 313-4. PubMed ID: 9339937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
    Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
    Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings.
    Páramo JA; Orbe J; Fernández J
    Thromb Haemost; 2001 Aug; 86(2):636-9. PubMed ID: 11522015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.
    Schol-Gelok S; de Maat MPM; Biedermann JS; van Gelder T; Leebeek FWG; Lijfering WM; van der Meer FJM; Rijken DC; Versmissen J; Kruip MJHA
    Br J Haematol; 2020 Sep; 190(6):916-922. PubMed ID: 32301122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.